Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* are at least 18 and less than 65 years;~* sign written informed consent after the scope and nature of the investigation have been explained;~* have shown capability to complete the LogPad questionnaires;~* have difficulty falling asleep, maintaining sleep or have early morning awakening;~Exclusion Criteria:~* Significant medical or psychiatric illness causing sleep disturbances.~* Have a history of bipolar disorder or attempted suicide or have a family (immediate family) history of suicide.~* Have a sleep disorder such as sleep-related breathing disorder, restless leg syndrome, narcolepsy.~* Significant other medical illness such as acute or chronic pain, heart-, kidney-, or liver disease within the last year.~* Currently diagnosed or meet the criteria for Major Depressive Disorder (MDD) or have been treated for MDD in the last 2 years.~* Substance abuse, excessive use of alcohol (determined by the physician) or drug addiction within the last year.~* Are night workers or rotating shift workers or plan to travel through more than 3 time-zones.~* Routinely nap during the day.~* Have a Body Mass Index (BMI) of 36 or more.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Esmirtazapine 4.5 mg (Type: EXPERIMENTAL): Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo tablets, administered once a day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).